Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enapotamab
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Enapotamab is a human monoclonal antibody (IgG1-kappa) that targets AXL, a member of the TAM (Tyro3, AXL, Mer) family of receptor tyrosine kinases. AXL is frequently overexpressed in various malignancies, including multiple myeloma, where it contributes to tumor cell survival, epithelial-to-mesenchymal transition (EMT), and resistance to therapy. While originally developed as the antibody component of the antibody-drug conjugate (ADC) enapotamab vedotin (HuMax-AXL-ADC), enapotamab is being investigated as a standalone therapeutic or in combination regimens. In the context of relapsed or refractory multiple myeloma, it is being studied in combination with mezigdomide (a CELMoD agent) to evaluate potential synergistic effects in overcoming drug resistance and improving clinical outcomes.
- Other names
- anti-AXL monoclonal antibody
02
Targets
AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on enapotamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enapotamab.